Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 27, 1998

View Archived Issues

Biogen: Q4 and FY 1997 highlights

Lilly and Allelix expand research programs

Chesapeake Biological Laboratories and LXR to codevelop Cardiosol products

New approach to cancer therapy reported

Lilly researchers prepare novel 5-HT reuptake inhibitors

Resistance modulators for use in cancer and malaria developed at Lilly

Protein farnesyltransferase inhibitors patented by Pfizer for cancer

Antifungal antibiotics isolated by Takara Shuzo

ADIR prepares MMP inhibitors for arthritis, cancer, atherosclerosis

Takeda discloses compounds that upregulate LDL receptors

ACAT-inhibitory anilides from Kowa are particularly useful for atherosclerosis

U.K. launch for Posicor

Wyeth-Ayerst licenses PEPCK-modulating compounds

New antimigraine combination addresses both headache and vomiting

Progenitor and Affymetrix collaborate on asthma research

New bacterial genomics company established by Theratechnologies

First pivotal trial of lisofylline completed

Mentor obtains marketing rights to new cancer therapeutic from Intracel

New ET antagonists from Merck KGaA bearing a benzothiadiazole functionality

AtheroGenics initiates phase I testing for new cardiovascular drug

Vion prepares more active prodrug of beta-L-FD4C

Phytochemistry alliance formed by Xenova Discovery and IGER

AltaRex reacquires Western European marketing rights to Ovarex

Once-daily hair loss treatment available throughout the U.S.

RTX enters phase II for urge incontinence

New once-daily rosacea therapy introduced in U.S.

Common variant of CETP gene correlated with atherosclerosis progression, response to pravastatin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...